Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Current Deferred Revenue (2018 - 2024)

Historic Current Deferred Revenue for Dna X (SONM) over the last 7 years, with Q2 2024 value amounting to $12000.0.

  • Dna X's Current Deferred Revenue changed N/A to $12000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $12000.0, marking a year-over-year change of. This contributed to the annual value of $12000.0 for FY2023, which is 6129.03% down from last year.
  • As of Q2 2024, Dna X's Current Deferred Revenue stood at $12000.0.
  • Dna X's Current Deferred Revenue's 5-year high stood at $872000.0 during Q2 2021, with a 5-year trough of $3000.0 in Q1 2023.
  • Over the past 5 years, Dna X's median Current Deferred Revenue value was $31000.0 (recorded in 2022), while the average stood at $166933.3.
  • In the last 5 years, Dna X's Current Deferred Revenue crashed by 9828.18% in 2020 and then surged by 30000.0% in 2024.
  • Dna X's Current Deferred Revenue (Quarter) stood at $5000.0 in 2020, then surged by 120.0% to $11000.0 in 2021, then soared by 181.82% to $31000.0 in 2022, then tumbled by 61.29% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024.
  • Its Current Deferred Revenue was $12000.0 in Q2 2024, compared to $12000.0 in Q1 2024 and $12000.0 in Q4 2023.